NeuroVive´s Clinical Phase II study for traumatic brain injury passes safety evaluation

Posted in Awards & Appointments on 14th Aug 2015

ACNRJA15-30aThe Swedish biotechnology company NeuroVive Pharmaceutical recently announced that the ongoing clinical Phase IIa study for traumatic brain injury with the company’s drug candidate NeuroSTAT® passed a safety evaluation and is moving on to the higher dosage group with the last 10 of 20 patients. The interim analysis included an evaluation of blood concentrations of cyclosporin A (the active substance in NeuroSTAT®) and changes in intracranial pressure and blood samples collected to analyze possible organ injury.

“We’ve now obtained important safety data on the lower dose of NeuroSTAT® for treating patients with traumatic brain injury and can now move on to treat patients with the higher dose. This means that the study has reached an important milestone in the clinical trial program of NeuroSTAT®,” commented NeuroVive’s CEO Mikael Brönnegård.

More information about the study can be found at:

ACNR 2015;15(3):30.  Online 30/07/15

Download this Article

Open Access, for medical professionals: Sign up to receive our email newsletter with links to the latest content. ACNR is free, thanks to the support of advertisers. The editorial content is peer reviewed and remains completely independent unless clearly specified. 

We may infrequently send you news from our sponsors which is relevant to the field of neurology, but you can opt out at any time.

See a sample email newsletter here
This website is for medical professionals only.